The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

NCT04671303 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

NCT00614809 ·Status: UNKNOWN ·Phase: PHASE2

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

NCT03742193 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

NCT00154739 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

NCT01772732 ·Status: UNKNOWN ·Phase: PHASE1

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

NCT01579630 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765 ·Status: TERMINATED ·Phase: PHASE4

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

NCT02356991 ·Status: SUSPENDED ·Phase: PHASE2

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

NCT02037997 ·Status: UNKNOWN ·Phase: PHASE2

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

NCT05549037 ·Status: RECRUITING ·Phase: PHASE3

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00536107 ·Status: TERMINATED ·Phase: PHASE4

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Personalized Therapy in Non-small Cell Lung Cancer

NCT01781988 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

NCT06829459 ·Status: RECRUITING ·Phase: PHASE3

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

NCT03203590 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib

NCT03629691 ·Status: COMPLETED

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

NCT03656393 ·Status: UNKNOWN ·Phase: PHASE3

Efficacy of Osimertinib in Patients With Lung Cancer

NCT06174857 ·Status: RECRUITING

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

NCT00874419 ·Status: COMPLETED ·Phase: PHASE3

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

NCT01039948 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NCT04871997 ·Status: COMPLETED

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

NCT05209256 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

NCT04197076 ·Status: UNKNOWN

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

NCT04977791 ·Status: RECRUITING

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

NCT04762459 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3